Please login to the form below

Not currently logged in
Email:
Password:

tucatinib

This page shows the latest tucatinib news and features for those working in and with pharma, biotech and healthcare.

UK approval for Seagen’s oral HER2 inhibitor Tukysa

UK approval for Seagen’s oral HER2 inhibitor Tukysa

The MHRA has cleared Tukysa (tucatinib) as an add-on therapy to Roche’s anti-HER2 antibody Herceptin (trastuzumb) plus Xeloda (capecitabine) for adults patients with HER2-positive locally-advanced or

Latest news

More from news
Approximately 2 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Acquisition company. 628. Cascadian Therapeutics/Seattle Genetics. Lead programme tucatinib, oral, small molecule TKI highly selective for HER2 (p2). ... Undeterred Seattle Genetics went on to buy Cascadian Therapeutics at the very end of January for

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

Menopause-thumbnail.png
Breaking the silence: It’s time to talk about the menopause
Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change....
Committing time to making meaningful connections - top 5 tips
Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
News:
Senior Analytics Specialist joins Research Partnership...